Total Payments
$78,558
2024 Payments
$41,036
Companies
27
Transactions
131
Medicare Patients
15,488
Medicare Billing
$6.0M
Payment Breakdown by Category
Consulting$37,650 (47.9%)
Research$27,922 (35.5%)
Other$6,936 (8.8%)
Food & Beverage$3,974 (5.1%)
Travel$2,056 (2.6%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,650 | 13 | 47.9% |
| Unspecified | $27,922 | 10 | 35.5% |
| Honoraria | $6,700 | 3 | 8.5% |
| Food and Beverage | $3,974 | 97 | 5.1% |
| Travel and Lodging | $2,056 | 5 | 2.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $235.53 | 2 | 0.3% |
| Gift | $19.40 | 1 | 0.0% |
Payments by Type
General
$50,636
121 transactions
Research
$27,922
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Iridex Corporation | $38,002 | 18 | $0 (2024) |
| Alimera Sciences, Inc. | $34,895 | 24 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $2,664 | 9 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $379.82 | 14 | $0 (2024) |
| Astellas Pharma US Inc | $348.52 | 7 | $0 (2024) |
| Integra LifeSciences Corporation | $335.39 | 4 | $0 (2023) |
| Dutch Ophthalmic, USA | $273.82 | 1 | $0 (2023) |
| Notal Vision, Inc. | $222.88 | 1 | $0 (2022) |
| Apellis Pharmaceuticals, Inc. | $205.29 | 5 | $0 (2024) |
| Genentech USA, Inc. | $201.16 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,036 | 38 | Iridex Corporation ($19,000) |
| 2023 | $8,121 | 27 | Iridex Corporation ($7,037) |
| 2022 | $12,345 | 21 | Iridex Corporation ($11,650) |
| 2021 | $3,268 | 6 | Alimera Sciences, Inc. ($3,200) |
| 2020 | $125.15 | 4 | Iridex Corporation ($90.45) |
| 2019 | $356.71 | 10 | Regeneron Healthcare Solutions, Inc. ($141.89) |
| 2018 | $5,038 | 11 | Alimera Sciences, Inc. ($4,820) |
| 2017 | $8,268 | 14 | Alimera Sciences, Inc. ($8,056) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Ophthalmology | ||||||
| 12/12/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $33.64 | General |
| Category: Ophthalmology | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $824.48 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $352.54 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $218.68 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/15/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $25.38 | General |
| 11/08/2024 | Amgen Inc. | PAVBLU (Biological) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Inflammation | ||||||
| 10/24/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: Ophthalmology | ||||||
| 10/18/2024 | Iridex Corporation | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 10/18/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $151.92 | General |
| Category: Ophthalmology | ||||||
| 10/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: Ophthalmology | ||||||
| 10/03/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/26/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: EYE CARE | ||||||
| 09/23/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/15/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $853.74 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 09/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $90.97 | General |
| Category: Ophthalmology | ||||||
| 09/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.38 | General |
| Category: Ophthalmology | ||||||
| 08/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/05/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/01/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $3,610.26 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Iluvien Study | Alimera Sciences, Inc. | $18,672 | 6 |
| PALADIN | Alimera Sciences, Inc. | $9,250 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 3,965 | 26,978 | $2.3M | $1.5M |
| 2022 | 23 | 3,974 | 12,080 | $2.2M | $1.5M |
| 2021 | 20 | 3,762 | 8,615 | $2.2M | $1.6M |
| 2020 | 21 | 3,787 | 8,278 | $2.1M | $1.4M |
Total Patients
15,488
Total Services
55,951
Medicare Billing
$6.0M
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 51 | 19,073 | $762,920 | $555,707 | 72.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 75 | 767 | $881,841 | $528,635 | 59.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 968 | 2,329 | $348,406 | $206,932 | 59.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 163 | 881 | $114,843 | $73,737 | 64.2% |
| 92134 | Imaging of retina | Office | 2023 | 730 | 1,380 | $71,067 | $41,411 | 58.3% |
| 92250 | Photography of the retina | Office | 2023 | 815 | 1,197 | $55,507 | $32,357 | 58.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 161 | 161 | $31,770 | $17,903 | 56.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 171 | 194 | $23,590 | $12,100 | 51.3% |
| 92273 | Measurement of retinal and optic nerve function | Office | 2023 | 59 | 71 | $10,511 | $6,316 | 60.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 399 | 457 | $9,168 | $5,234 | 57.1% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 26 | 86 | $8,170 | $4,812 | 58.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 32 | 33 | $5,400 | $3,500 | 64.8% |
| 92133 | Imaging of optic nerve | Office | 2023 | 115 | 123 | $5,782 | $3,023 | 52.3% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 15 | 15 | $4,181 | $2,969 | 71.0% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 55 | 60 | $4,419 | $2,476 | 56.0% |
| 95930 | Measurement of nerve conduction using visual stimulation testing with report | Office | 2023 | 29 | 45 | $3,330 | $2,239 | 67.3% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 70 | 73 | $2,485 | $1,286 | 51.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 31 | 33 | $1,952 | $1,200 | 61.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 115 | 1,104 | $1.1M | $789,236 | 72.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 977 | 2,273 | $339,251 | $202,855 | 59.8% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 29 | 3,660 | $146,400 | $109,219 | 74.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 16 | 353 | $141,200 | $80,288 | 56.9% |
| J3490 | Unclassified drugs | Office | 2022 | 17 | 45 | $112,600 | $79,092 | 70.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 173 | 883 | $113,766 | $73,311 | 64.4% |
| 92134 | Imaging of retina | Office | 2022 | 749 | 1,385 | $66,942 | $42,666 | 63.7% |
About Dr. Sam Mansour, MD
Dr. Sam Mansour, MD is a Ophthalmology healthcare provider based in Warrenton, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376506873.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sam Mansour, MD has received a total of $78,558 in payments from pharmaceutical and medical device companies, with $41,036 received in 2024. These payments were reported across 131 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($37,650).
As a Medicare-enrolled provider, Mansour has provided services to 15,488 Medicare beneficiaries, totaling 55,951 services with total Medicare billing of $6.0M. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Warrenton, VA
- Active Since 04/07/2006
- Last Updated 04/11/2025
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1376506873
Products in Payments
- ILUVIEN (Drug) $21,987
- ILUVIEN (Biological) $8,000
- EYP-1901 (Drug) $2,599
- Iluvien (Drug) $1,288
- Integra (Device) $335.39
- EVA, combined machine (Device) $273.82
- Izervay (Drug) $249.84
- Syfovre (Drug) $182.43
- EYLEA (Biological) $175.21
- Cimerli (Biological) $148.60
- OZURDEX (Drug) $147.71
- BEOVU (Drug) $141.05
- EYLEA AFLIBERCEPT INJECTION (Biological) $126.84
- XIPERE (Drug) $115.98
- EYLEA HD (Biological) $112.98
- Vabysmo (Drug) $89.28
- Lucentis (Biological) $57.68
- Susvimo (Drug) $49.05
- YUTIQ (Drug) $48.70
- VISUDYNE (Drug) $46.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Warrenton
Dr. Marena Patronas, M.d, M.D
Ophthalmology — Payments: $2,510
Ophthalmology $2,510
Dr. Malkit Singh, Md Mpa, MD MPA
Ophthalmology — Payments: $1,653
Ophthalmology $1,653
Alessa Crossan, M.d, M.D
Ophthalmology — Payments: $1,280
Ophthalmology $1,280
Alexandre Gauthier, M.d, M.D
Ophthalmology — Payments: $1,132
Ophthalmology $1,132